Literature DB >> 17874861

[The role of voriconazole in the treatment of emerging mycoses].

F Javier Pastor1, Josep Guarro.   

Abstract

Voriconazole is a broad-spectrum antifungal drug belonging to triazoles class. Recently, it has been recommended for the treatment of invasive candidiasis in non neutropenic patients. In addition, this drug has showed clinical efficacy in the treatment of fungal infections caused by Candida species other than Candida albicans, and also in several other infections caused by less common fungi, such as Aspergillus terreus, Fusarium and Scedosporium.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17874861     DOI: 10.1016/s1130-1406(07)70048-7

Source DB:  PubMed          Journal:  Rev Iberoam Micol        ISSN: 1130-1406            Impact factor:   1.044


  4 in total

1.  Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.

Authors:  Eriques Gonçalves Silva; Claudete Rodrigues Paula; Amanda Latercia Tranches Dias; Marilene Rodrigues Chang; Luciana da Silva Ruiz; Valderez Gambale; Renato Araujo Prates; Martha Simões Ribeiro
Journal:  Mycopathologia       Date:  2010-10-24       Impact factor: 2.574

2.  Less-frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility.

Authors:  Mónica Azor; Josepa Gené; Josep Cano; Palanisamy Manikandan; Narendran Venkatapathy; Josep Guarro
Journal:  J Clin Microbiol       Date:  2009-03-25       Impact factor: 5.948

3.  Efficacy of triazoles in a murine disseminated infection by Candida krusei.

Authors:  Marçal Mariné; F Javier Pastor; Carolina Serena; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

4.  Susceptibility testing and molecular classification of Paecilomyces spp.

Authors:  Maria Victoria Castelli; Ana Alastruey-Izquierdo; Isabel Cuesta; Araceli Monzon; Emilia Mellado; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.